Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with rio...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
19 December 2018
|
| In: |
Respiratory research
Year: 2018, Jahrgang: 19 |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-018-0957-y |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1186/s12931-018-0957-y
|
| Verfasserangaben: | Alberto M. Marra, Michael Halank, Nicola Benjamin, Eduardo Bossone, Antonio Cittadini, Christina A. Eichstaedt, Benjamin Egenlauf, Satenik Harutyunova, Christine Fischer, Henning Gall, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Tobias J. Lange, Karen M. Olsson, Hans Klose and Ekkehard Grünig |
Search Result 1
Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
BioMed Central 19 December 2018 Universitätsbibliothek Heidelberg 19 December 2018
Article (Journal)
Buch/Monographie
Online Resource